J&J to pay $181 million for Risperdal settlement

Share this article:
J&J to pay $181 million for Risperdal settlement
J&J to pay $181 million for Risperdal settlement
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.
 
The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.
 
Although it is legal for physicians to prescribe drugs such as Risperdal for unapproved indications, manufacturers are forbidden from promoting the drug to providers for such uses. Risperdal often is used in nursing homes to sedate agitated memory care residents. Regulators and provider groups have been working to reduce this practice.

J & J has been involved in several multimillion-dollar settlements with regard to Risperdal in recent months. In March, federal prosecutors rejected a $1 billion settlement with J & J over Risperdal.
Share this article:

More in News

CMS needs to get nursing home staffing information directly from payroll systems, Congressional leaders say

CMS needs to get nursing home staffing information ...

Federal regulators should start collecting nursing home staffing information directly from payroll systems as soon as possible, members of the Congressional Seniors Task Force said in a letter to a ...

Male CNA who wears women's clothing can pursue charges that nursing home ...

A Texas certified nursing assistant can continue to pursue charges that his former nursing home employer has made false, defamatory statements about him in the job referral process, a federal court recently ruled.

High-profile consumer advocacy group sues over broken Medicare appeals process

Long-term care providers have been outspoken in their criticism of the Medicare appeals process, which has all but ground to a halt. Now a class-action lawsuit says Medicare beneficiaries also are being harmed by the excessively long delays.